Latest Farm Bill Developments Hold Out Hope for Hemp Farmers

CannabisNewsWire Editorial Coverage: After years of wrangling, the U.S. Congress stands on the verge of legalizing the cultivation of industrial hemp.

  • Hemp is a variety of the cannabis sativa plant that doesn’t generate a psychoactive effect.
  • Traditionally used to produce cloth and rope, hemp can also now be used in wellness products and food.
  • Competing legislations by the House and Senate are being aligned with an anticipated September 30 deadline.
  • The legalization of hemp has cross-party support and appears likely to pass.

The expected change in U.S. law will be beneficial for companies such as Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile), which is already invested in industrial hemp and support for hemp growers. Across the border, Canopy Growth Corp. (NYSE: CGC) has established acres of Canadian hemp cultivation and gained financial backing that would support huge growth. Aurora Cannabis, Inc. (OTCQX: ACBFF) has also received substantial funding in the past few months, which will help its ongoing expansion effort. Hemp cultivation will provide plentiful CBD to be used by companies such as CV Sciences, Inc. (OTC: CVSI) as an ingredient in a wide and growing range of health and wellness products. All this growth is aided by support companies such as Terra Tech Corp. (OTC: TRTC), which provides equipment for cannabis cultivators.

To view an infographic of this editorial, click here.

Hemp: Caught Between Politics and Business

Industrial hemp is a crop with a strange history in the United States. For centuries, it was used to produce products such as ropes and sails, playing an integral part in the economy. This ended in the twentieth century when hemp was caught up in a broad ban on the cannabis family of plants, despite the fact that hemp itself is not usable as a recreational drug. Now its tentative return depends upon the outcome of a far broader agricultural bill.

Because it doesn’t share the psychoactive properties of marijuana, hemp has potential to be regulated and grown separately. Early tests in restoring this industry have produced significant profits for farmers. If the political will can be found to change its status, it could create great opportunities for businesses and their suppliers.

Hemp Cultivation Project in the United States

Several companies, including Marijuana Company of America (OTC: MCOA), are already growing hemp in the United States with their Scio, Oregon Cultivation Project, in conjunction with their joint venture partner Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FRANKFURT: GHG).

Under their high-yielding CBD hemp cultivation projects, the two joint venture partners have formed Covered Bridge Acres, LTD. The key to the project was the acquisition of a 109-acre agricultural property in Scio, Oregon, with a history of hemp cultivation over the past few years. In July 2018, 40,000 hemp clones were planted on the property for Cannabidiol (CBD) propagation on approximately 33 acres of the property.

MCOA and GHG are now in the process of evaluating different harvesting, drying, storage and processing strategies in preparation of an early October harvest. The joint venture partners are also in negotiations with guaranteed offtake agreement offers and are considering strategies involved with selling the attained biomass from harvest in bulk.

When Is a Drug Not a Drug?

Hemp is one of a range of different cannabis plants. Unlike the versions smoked by recreational users, it doesn’t contain significant quantities of tetrahydrocannabinol (THC), the chemical that gets smokers high. It does contain the active ingredient cannabidiol (CBD), which has been widely reported to have medicinal value — reports that now have been substantiated by the U.S. Food and Drug Administration. Importantly, hemp also contains fibers that can be used for a wide range of purposes.

In the twentieth century, cannabis plants were banned as the U.S. government and others worldwide cracked down on drug use. Though hemp doesn’t get drug users high, the governments apparently banned the cannabis plant because of the difficulty of distinguishing between the plant varieties. The decision to include hemp in a list of banned drugs was based on political expediency rather than science.

Fast forward to the twenty-first century and the rules surrounding hemp have started to change, allowing the creation of companies such as MCOA. Hemp has a huge number of potential uses, including the manufacture of cloth and paper and the processing of food. Under licenses designed to cater to research and the medical market, farmers have begun growing industrial hemp with expectations of earning up to 150 times as much money per acre of land as they would growing alfalfa.

The Great Agricultural Debate

Farm bills are an important part of how the U.S. government establishes policy around food and agricultural production and how that policy is enshrined in law. Roughly every five years, Congress creates a bill covering a wide range of agricultural topics. With its huge financial implications and many different political angles, passing the bill can be a messy business.

Following a pilot research program for hemp growers created in the 2014 Farm Bill, the current Farm Bill includes the legalization of industrial hemp. There’s a lot at stake for hemp growers as well as those hoping to enter and establish a foothold in the industry. The U.S. Hemp Roundtable has gone so far as to hire attorney Daniel Cameron, an experienced Washington legal counsel, to lead its advocacy on the bill.

The House and Senate have both passed versions of the 2018 Farm Bill that support the legalization of the hemp industry without drug enforcement oversight. On Sept. 5, the first bicameral conference committee on this Farm Bill began meeting in an attempt to resolve competing elements between the two bills, with a deadline to present the president with an agreed-on final version of the bill by the end of the month.

The good news for companies such as MCOA is that the hemp element of the Farm Bill has cross-party support. Hemp’s potential to revive the fortunes of American farmers makes it a potential vote-winner for rural politicians nervously eyeing up the polls. The bad news is that in a bill affecting everything from agricultural subsidies to environmental conservation to food stamps, there’s plenty for politicians to disagree over.

Hemp Products

Sail cloth and rigging were enough to make hemp profitable in the eighteenth century, but the world has changed since then. So what sort of products can the world expect to see from a resurgent hemp market?

Many products will undoubtedly be targeted towards the health and wellness market, using CBD as an active ingredient. A leading example of these types of products is MCOA’s hempSMART line, including hempSMART Brain, which is developed to help with alertness and concentration; hempSMART Pain Capsules and Pain Cream, formulated to be an effective product combination for the temporary relief of minor pain associated with physical activity; hempSMART Full Spectrum Drops; and hempSMART Face, a nourishing facial moisturizer infused with Ayurvedic herbs and botancials.

A Growing Industry

Many companies already engaged in the cannabis market are exploring ways they may be able to benefit from the growing popularity of hemp. Canopy Growth Corp. (NYSE: CGC), one of Canada’s foremost cannabis companies, has a hemp division with expertise in this area and acres of hemp production already under way. The company also recently received a $4 billion investment from Constellation Brands, a leading beverage company, to help it expand within the fast-growing cannabis market. With such levels of investment, Canopy Growth will be in a strong position to increase production as the market for hemp products grows.

The medical use of CBD is a major area of interest for Aurora Cannabis, Inc. (OTCQX: ACBFF), which is developing different strains of cannabis to benefit from their different medical properties. Like Canopy Growth, Aurora has an eye to expansion while the market is still young. Its recent takeover of MedReleaf appears to be just one step in a far bigger plan. The company has just taken out a $150 million loan with the Bank of Montreal, betting on the power of a short-term financial boost to make it a market leader, more than capable of repaying the debt when the time comes.

Another company exploring the medical potential of CBD is CV Sciences, Inc. (OTC: CVSI). CV Sciences has a strong focus on research, with a division devoted to developing new drugs that use CBD as an active ingredient. Its consumer products division works through health care providers, health food shops and online sales to market CBD-based wellness products.

The increasing number of growers is good news for supporting companies such as Terra Tech Corp. (OTC: TRTC). Terra Tech produces growing systems — including moving tables and hydroponics — for cannabis farmers. These products are designed to increase the productivity of indoor cannabis cultivation, which is where a lot of CBD and marijuana plants are grown. The company’s environmentally friendly systems can reduce waste and thereby cut costs while also increasing productivity.

The anticipated changes in the U.S. laws governing hemp cultivation signal implications for a large number of companies in the wider cannabis sector as well. If the Farm Bill gets through Congress as expected this month, it could open up a sea change in agricultural production and U.S. wellness industry products.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA

CannabisNewsWire Editorial Coverage: In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).

  • FDA approval of a cannabis-based drug represents seismic political, legal and economic shifts
  • Approval likely will lead to more clinical research and further validation of CBD therapeutic efficacy
  • CBD market projected to explode to more than $2 billion in two years with 39 percent CAGR

What’s most transformative about this drug approval is that this is the first time the FDA — the governmental arbiter of safe and effective medicine in the United States — has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.

CBD, a non-psychoactive cannabinoid that can be extracted from the industrial hemp plant, is understandably generating worldwide interest from both the scientific and investment communities. A large part of CBD’s mass appeal is that it’s believed to aid with a broad range of wellness concerns. CBD is known to interact with the human endocannabinoid system, which is found throughout the body’s nervous system, organs, connective tissues, glands and immune system. Research indicates CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues and chronic pain. It’s being researched to treat Alzheimer’s, and one study even suggests CBD might be a useful addition when given with conventional antipsychotic medications in the treatment of schizophrenia.

Continued rigorous clinical research is being conducted to further confirm all the potential therapeutic benefits that may be found in this cannabinoid extract. In the meantime, the mass appeal of CBD remains unabated, and the market for CBD products continues to grow at an astounding rate. Committed to the legal hemp-derived CBD market, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) provides consumers with pure, hemp plant-based CBD nutritional products through its global hempSMART™ brand and has initiated broad-ranging, innovative cultivation programs for legal, high-quality hemp. Others vying for position in the burgeoning CBD space include Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV Sciences, Inc. (OTC: CVSI), PotNetwork Holdings, Inc. (OTC: POTN) and Medical Marijuana, Inc. (OTC: MJNA).

The Boom Has Just Begun

Three years ago, in 2015, the hemp-derived CBD market racked up $90 million in sales. Last year that number reached $190 million in sales — and the boom has just begun. The Hemp Business Journal projects $2.1 billion in total CBD sales by 2020 and estimates that $450 million of that will come from hemp-based sources. The explosive demand projections are attributed to an increased public awareness of the wide-ranging potential health benefits of hemp CBD oil and advancements in cultivation, plus the convenience and reach of online retailing — all of which contribute to a global CBD oil market expected to grow at an eye-popping CAGR of 39.19 percent through 2021.

Hemp Focus

With an overarching focus on the cultivation, development and distribution of legal industrial hemp-derived products, Marijuana Company of America (OTC: MCOA) aims to capture an outsized share of growing worldwide demand. Pure hemp-based consumer nutritional products are at the core of this demand,  and the company has developed a portfolio of ancillary hemp-centric businesses to vertically integrate hemp production and sales. Cultivation of high-quality hemp from portfolio companies feeds MCOA’s proprietary CBD-based formulations, dovetailing to produce the finest quality nutritional supplements on the market.

The unique company vision emanates from Donald Steinberg, MCOA’s CEO. A cannabis industry pioneer, he founded the first cannabinoid-centric company to trade on a U.S. stock market. His vast knowledge and industry experience give MCOA unparalleled insights into the machinations of the CBD markets and the vision to capitalize on industry opportunities in a market projected to exceed $2 billion in the coming years. In keeping with this ambitious strategy, Steinberg and his partner, Charlie Larsen, formed Marijuana Company of America as well its sister company, Canadian-based Global Hemp Group, Inc. (OTC: GBHPF), which is focused on the legal cultivation and processing of industrial hemp. MCOA continues to build an impressive portfolio of synergistic companies across the hemp spectrum. From farm to finished products, MCOA’s socially conscious strategy is to capitalize at each profit point and establish a significant footprint at multiple inflection points across the entire hemp value chain.

Hemp-Based Nutritionals

MCOA has worked to create a recognized and respected hempSMART product line that contains levels of clinically researched ingredients designed to exceed consumer expectations and support the body’s natural endocannabinoid system. To serve health-conscious consumers, hempSMART includes an array of proprietary nutritional products.

  • hempSMART Brain is a patent-pending formulation designed for optimal brain function support.
  • hempSMART Drops offer the highest concentration and potency of full-spectrum bioavailable CBD.
  • hempSMART Pain Capsules contain a blend of premium CBD and botanical supplements.
  • hempSMART Pain Cream is a proprietary formulation for relief from muscle and joint pain.
  • hempSMART Full Spectrum Pet Drops is a unique nutritional supplement designed for furry family members.
  • hempSMART Face is a topical face moisturizer that combines CBD oil with ayurvedic herbs and botanicals.

MCOA’s hempSMART goes through an exacting CO2 extraction process to ensure the highest quality in the company’s natural wellness product line. By combining these pure industrial hemp-based cannabinoids with some of nature’s most effective wellness ingredients, MCOA’s hempSMART products are poised to deliver optimally formulated wellness products to health-conscious consumers.

In a forward-thinking plan to expand retail distribution and capitalize on impulse buys in high-traffic stores, MCOA took a 25 percent equity stake in BeniHemp-branded CBD products. BeniHemp health-focused products include topicals, tinctures and edibles packaged in one-day, two-day and thirty-day supplies widely distributed to convenience stores, smoke shops, gas stations and small retail outlets.

A Growing Portfolio

In addition to the hempSMART and BeniHemp consumer products lines, MCOA continues to strategically assemble synergistic portfolio companies. In a joint venture with sister company Global Hemp Group, MCOA launched a 125-acre industrial hemp cultivation project in northeast New Brunswick, Canada. The project targets the promotion of hemp farming while providing year-round jobs in crop and finished product processing.

Also in conjunction with Global Hemp Group, MCOA is developing Covered Bridge Acres, an innovative high-yielding CBD hemp cultivation project in Oregon. The project utilizes both traditional outdoor cultivation and what will ultimately become more than 19,000 square feet of indoor greenhouses, which are slated to eventually supply the raw oil needed for the hempSMART CBD product line.

MCOA also took a 15 percent equity stake in MoneyTrac Technology, Inc., a subsidiary of Global Payout, Inc. (OTC: GOHE). MCOA made this investment to help establish and market MoneyTrac Technology as an alternative banking solution for the cannabis industry.

Others Vying for Position

Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) grows and harvests hemp on an industrial scale then processes it to extract the cannabidiol for distribution. The company commercializes pharmaceutical-grade cannabinoids, micro-encapsulations and nanotechnology for consumable and topical skin care products. Isodiol has announced plans to develop additional over-the-counter and pharmaceutical drugs, expand its phytoceutical portfolio and expand into Latin America, Asia and Europe.

CV Sciences, Inc. (OTCQB: CVSI) operates in two business segments. The company’s drug development division develops and commercializes novel therapeutics utilizing synthetic CBD. Its consumer product division manufactures, markets and sells plant-based CBD products to a range of market sectors. The company is also developing and pursuing FDA approval for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient.

Founded by MCOA CEO Donald Steinberg in 2009, Medical Marijuana, Inc. (OTC: MJNA) was the first U.S.-traded CBD company. The company develops, distributes and sells hemp oil that contains naturally occurring cannabinoids, including CBD. The company sells its hemp-derived CBD products through a variety of distribution subsidiaries. The company was among the first to bring hemp-based CBD oil products to market in the United States and the first to receive federal government import approvals in Mexico, Paraguay and Brazil.

PotNetwork Holdings, Inc. (OTC: POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co.; Diamond CBD, Inc.; and Sunrise Auto Mall, Inc. Diamond CBD focuses on the research, development and multinational marketing of hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD’s team consists of hemp industry professionals, chemists, doctors and scientists — all working together to produce CBD oils.

Seismic Shift

Modern science has begun to substantiate both the anecdotal history and the therapeutic efficacy of cannabidiol. The FDA’s recent approval of a cannabis-based drug represents a seismic shift and is further indication of the enormous curative potential that may be found in CBD. As more scientific validations ensue, the market for CBD products could easily exceed expectations, and well-positioned companies in the space could outperform the market.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

$1 Trillion Global Health and Wellness Sector Presents Growing Opportunities for Cannabidiol Companies

CannabisNewsWire Editorial Coverage: Cannabidiol (CBD) products are reaching into the mainstream through a growing health and wellness sector, and savvy companies are looking to position themselves to make the most of this momentum.

  • The health and wellness market grown to over $1 trillion globally as of 2017
  • Positive shifting regulations globally is opening major international markets to CBD products, especially CBD infused food, beverages and natural health products
  • Larger fortune 500 level food and beverage companies are beginning to consolidate this major growth market via major investments and mergers and acquisitions.

In a groundbreaking move, Phivida Holdings, Inc. (CSE: VIDA) (OTCQX: PHVAF) (PHVAF Profile) has become the first CBD company to have their CBD food, beverage and natural health products cross over into major national mainstream grocery distribution in the United States. Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is also expanding CBD’s reach through a growing chain of vaping shops. And the potential for wellness beverages is demonstrated by Koios Beverage (CSE: KBEV) (OTC: SNOVF), with its expanding range of brain-boosting drinks. Within the cannabis market, The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is providing organic, sustainable cannabis, a source of CBD that meets other consumer interests. And CV Sciences, Inc. (OTC: CVSI) is researching new CBD products and searching for ways to bring those products to market as the sector continues to grow in size and diversity.

Adding to Health and Wellness

The health and wellness sector is currently huge business. Conservative analysis places its value at over $1 trillion, while at least one commentator cites figures as high as $3.7 trillion. The willingness to make purchasing decisions based on better health and a longer life is no longer a niche interest. From gyms to health foods to counseling, consumers are spending a growing proportion of their income on creating healthier, happier lives.

Cannabidiol (CBD) products have become significant recent additions to the wellness market. Derived from cannabis plants, CBD is an active ingredient that has shown many potential health benefits without the intoxicating “high” provided by cannabis’ other main active ingredient, the THC found in marijuana. Research into CBD is still in its infancy, but that research has shown the ingredient’s potential to improve wellness in several ways. As legal changes make it easier to develop and produce CBD products, those products appear set to take an important place in the health and wellness market.

Reaching into the Grocery Market

One of the companies benefiting from this trend is Phivida Holdings, Inc. (CSE:VIDA) (OTC:PHVAF). Phivida (pronounced “fii-vee-daa”) is a producer of premium hemp oil extracts and capsules, the company provides health-conscious customers access to the benefits of CBD without unnatural chemicals. With a new C-suite management team in place consisting of former senior executives of Red Bull, Proctor & Gamble, Labatt’s and the former CEO of Seagram’s International, Phivida is now preparing to launch a CBD-infused beverage brand and has found a major partner to work with to ensure this strategic move is successful.

Phivida recently announced a groundbreaking exclusive national agreement with Acosta, Inc., a sales and marketing leader for the consumer-packaged goods industry in the United States, to distribute Phivida’s products, including the new beverage. Distributed through Acosta’s Natural Specialty Sales (NSS) division, Phivida’s drinks will be the first CBD hemp brand to cross over into the national mainstream distribution system in the states.

Natural specialty groceries are a significant market in North America, currently valued at USD $4.1 billion and growing. Obtaining a foothold in this market marks a historic milestone for CBD products, as well as a commercial coup for Phivida. NSS’s reach extends into 2,400 regional natural specialty grocery stores and the potential to expand into over 25,000 major national grocery stores across the U.S, including leading retailers such as Whole Foods, Sprouts, Walmart, and Kroger’s.

The major disruptive nature of the rapidly expanding cannabis and CBD-hemp markets have begun to draw attention from big players in the food and beverage industry as well. For example, Constellation Brands (NYSE: STZ) behind Corona beer and Svedka vodka, recently made a major investment in cannabis company Canopy Growth. And Southern Glazer’s, North America’s biggest wine and spirits distributor, has created a Canadian subsidiary to sell cannabis-infused products.

This trend is one that other major food, beverage and alcohol companies will almost certainly follow. As the market for CBD products grows, forward-thinking organizations will be looking for mergers and acquisition opportunities with CBD companies to gain exposure to this fast-growing market and protect their positions against disruption from the global cannabis sector.

Changing Regulations Drive Growth

The growth of the CBD sector is being driven by a global shift in the legal status of cannabis.

In the United States, regulated cannabis is now legal for both medical and recreational use in a number of states. On a national level, the Senate and House of Representatives are working to resolve differences between the two Congressional bodies’ versions of the 2018 Farm Bill, which include action to legalize industrial hemp. If the pro-hemp language remains in the final version of the bill, it would mark a significant shift in policy at the federal level, making it easier for businesses across the country to grow hemp and produce CBD products derived from it.

In Canada, the passing of Bill C-45 is set to make recreational cannabis legal across the country in October. The bill also includes rules for the production and sale of CBD-infused food and drink, creating a market for companies such as Phivida to sell new products as early as 2019.

Such moves are supported by the work of major global bodies. The World Health Organization (WHO) recently completed a report that found CBD is neither toxic nor addictive, making it safe for consumption. The report also highlighted CBD’s health benefits. The World Anti-Doping Agency (WADA) has removed CBD from its list of prohibited substances, allowing athletes to use it for treatment of pain and inflammations.

Making the most of this shift, Phivida is focusing on establishing an international presence. The deal with Acosta will provide distribution into a network of more than 27,000 U.S. retail outlets. In Canada, the company has created a joint venture with WeedMD to be the first to market with one of the first-ever federally legal cannabis beverage manufacturing facilities in the world — a major milestone. A deal with Namaste Technologies means Phivida products open the European Union and United Kingdom markets, while another deal with Asayake provides new opportunities for distribution in Japan. These partnerships have helped establish Phivida as the fastest-growing brand in CBD foods and beverages just as that market appears ready to take off.

Building a Business

Of course, CBD isn’t a magic product that will instantly give businesses success. Phivida’s achievements have been made possible by a skilled management team with experience in the beverages sector.

The company’s chief officers are all veterans of Red Bull’s North American operations, where they helped build the energy drink category from nothing to $300 million a year. CEO James Bailey worked as president of Red Bull Canada and held senior positions at Merrell Outdoors, Beneath Apparel, Adidas, Blue Goose and Salomon. Chief Marketing Officer Michael Cornwell is a former director of marketing at Red Bull Canada and was CMO at both Samsung NZ and Microsoft NZ. Chief Commercial Officer Doug Campbell was previously director of sales at Red Bull North America and director of national accounts at Stoli Group. The company’s advisers and directors also bring a powerful raft of experience to their roles, including time spent in senior management at Proctor and Gamble, in executive management at Labatt’s, and as CEO at Seagram’s International.

This powerful team is committed to ensuring Phivida operates with a tight capital structure. The company has more than $15.5 million CAD in cash and no debt. Just over 60 million shares have been distributed or are outstanding. With a fully diluted total of 71 million shares available, the company has ready access to approximately CAD $29 million in cash. With a strong leadership team and financial foundations, Phivida has achieved the first crossover of CBD beverages into major national mainstream retail distribution across the United States, as well as globally.

Surge of CBD

Regulatory change and consumer interest are also driving growth for a range of CBD and wellness businesses.

Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) provides a wide range of CBD products. Through its KURE Corp. subsidiary, the company strongly promotes CBD in vaping products. KURE recently announced plans to expand its retail footprint by opening new premises and acquiring existing vaping stores.

 Koios Beverage (CSE: KBEV) (OTC: SNOVF) is a manufacturer and distributor of drinks and supplements designed to boost brain function, enhance health and improve productivity. The company recently announced the release of four new flavors of its brain-healthy drinks. Like Phidiva, Koios is turning beneficial supplements into beverages, making the drinks more appealing to a wide market.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) produces cannabis tailored to the wider interests of health and well-being customers. Many of these consumers are deeply concerned with environmental issues, and the company’s organic, sustainably grown cannabis means that its products live up to these ethical standards.

 CV Sciences, Inc. (OTC: CVSI) is a CBD company with two distinct divisions. The pharmaceuticals part conducts research to develop new products, thereby expanding the possibilities of CBD. Meanwhile, the consumer products division focuses on getting those products to market.

The intersection of the CBD and wellness sectors is creating opportunities for businesses and consumers alike. As laws, attitudes and expectations continue to change around the world, these opportunities will only continue growing.

For more information about Phivida Holdings, please visit Phivida Holdings, Inc. (CSE:VIDA) (OTCQX:PHVAF)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Cannabidiol Market Anticipates Growth as Regulatory Change Looms in U.S.

CannabisNewsWire Editorial Coverage: Restrictions in the United States on cannabidiol (CBD), an active ingredient in cannabis, appear likely to loosen over the next few months, creating opportunities for CBD production and distribution companies.

  • CBD is an active ingredient with medical benefits but no “high”, or pyshcoactive effects.
  • The Food and Drug Administration (FDA) has approved a CBD-based medicine for the first time.
  • Companies are cultivating hemp to develop high yielding CBD plants.

Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is cultivating industrial hemp for CBD  propagation at sites in the United States and Canada while continuting to develop and manfuacture CBD-based products for its hempSMART™ brand. Cronos Group, Inc. (NASDAQ: CRON) is expanding its global reach for cannabis products through deals covering the United States, Canada, Australia and Poland, as this sector of the economy goes global. CV Sciences, Inc. (OTC: CVSI) is providing a clean bill of health for its CBD wellness products. Terra Tech Corp. (OTC: TRTC) is providing advanced hydroponic growing systems that increase crop yields and reduce costs for CBD-oriented companies. Manufacturer Liberty Health Sciences (OTC: LHSIF) produces cannabis in facilities recently certified as meeting high standards for manufacturing.

FDA Leads the Way to Reclassify Cannabidiol

The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks. For the first time, the FDA has approved a medicine that uses cannabidiol (CBD) as its active ingredient. CBD is a compound that can be found in the hemp and cannabis plants, but unlike tetrahydrocannabinol (THC) it does not get users high.

Repeated studies have demonstrated the beneficial effects of cannabinoids. As a result, cannabis products have been approved for medical use in many states, but this is the first time that a cannabinoid-based CBD product has been approved at the federal level. This approval represents a softening of the federal government’s attitude. CBD was previously classified as a Schedule I drug by the Drug Enforcement Agency, but this body is now expected to change its stance within the next three months, allowing the possibility to manufacture products that would currently be banned on the national level. This possibility represents a huge moment for the CBD industry.

Better Plants for Better Health

One of the companies likely to benefit from this change is the Marijuana Company of America, Inc. (OTC: MCOA). The company is focused on the cultivation of industrial hemp and the manufacturing of hemp-derived CBD products, and is expanding its operations to better serve its growing market.

The most recent addition to the company’s operations is an industrial hemp cultivation site in Scio, Oregon. Created in collaboration with Global Hemp Group (GHG), this is a 109-acre site in the Willamette Valley. With its rich soil and pre-existing irrigation infrastructure, the valley provides an ideal location for an agricultural project that has already been home to cannabis cultivation in the past.

The Scio facility uses a mixture of cultivation practices. It has 19,000 square feet of greenhouse growing space under construction alongside fields for outdoor crops. This will allow the company to produce a steady supply of hemp all year, with high-yield plants ensuring a significant volume of output.

One of the main aims of the team working at Scio is to encourage plant strains that have a particularly high yield of CBD. Careful data collection and analysis are being used to assess the quality of plants and the effectiveness of techniques used to grow them. The expected change in the legal status of CBD in the United States will make it easier for MCOA to conduct research and cultivate CBD rich industrial hemp like at the Scio site, and for patients to have access to the products that come from it.

Working with Government to Improve Agriculture

MCOA and GHG are also collaborating on a similar project in New Brunswick, Canada, on a much larger scale. For this project, the two companies are working with the New Brunswick Department of Aquaculture, Agriculture and Fisheries (DAAF) to explore better approaches to growing hemp.

With markets for hemp and CBD reaching greater maturity, the DAAF has shown its faith in the future by awarding a grant of $10,750 to the joint MCOA and GHG venture in the region. These funds will be used on test projects for the current crop season, which will allow the companies to improve their cultivation techniques.

These government-funded tests are focused on three areas, two of which are looking at soil conditions to identify the best levels of nitrogen fertilizer for crops and whether soil acidity can be effectively adjusted using local supplies of slag lime. The third area of study is the European corn borer, a moth that damages crops and that has been a pest to farmers in the region. Damage from borers was found on hemp stalks last year, so the companies will be looking at the impact this damage could have on cultivation.

The latest technology is being used to ensure the success of these tests. A drone company has been employed to provide overviews of growth across hemp fields because the height of the stalks and density of cultivation makes assessment by other means difficult. With agricultural experiments underway in both Canada and the United States, MCOA has multiple opportunities to cultivate better CBD crops.

In New Brunswick, the two companies have created what they refer to as the Hemp Agro-Industrial Zone (HAIZ), where they are carrying out trials of hemp cultivation targeted at developing the industry in the province. By exploring cultivation techniques, ensuring a market for the product and providing consistent jobs for local farm workers, they aim to create a green-industry cluster specializing in hemp.

Creating Wellness

MCOA isn’t just a cultivation company. It is manufacturing its hemp crops into a wide range of products formulated to improve the well-being of customers.

Much of this work is carried out through hempSMART, the company’s most prominent consumer brand. HempSMART creates CBD-based wellness products and provides consumers with education about the potential benefits CBD may provide. Many consumers don’t understand the difference between CBD and THC products. Through hempSMART, MCOA is raising awareness while reaching out to a growing market.

The most recent release from hempSMART is the relaunch of its hempSMART Brain product. This version doubles the dose of CBD from the original, combining CBD oil with a blend of natural plant-based ingredients. Designed to maintain mental clarity, alertness, focus and concentration, as well as promote relaxation, restorative sleep, and the repair and regeneration of brain cells, hempSMART Brain is a flagship product that demonstrates MCOA’s wellness agenda. With the prospect of a change in the CBD compound’s legal status in the United States, companies such as MCOA will have more opportunities to develop and sell these types of products, spreading CBD-based wellness.

Growing Companies Profit from Changing Regulations

A range of companies in the cannabinoid sector will be in a position to profit from this change. Cronos Group, Inc. (NASDAQ: CRON) is demonstrating the global potential of cannabinoid products. The North American company already has a cross-border deal that allows it to make use of advances in both Canada and the United States. In addition, Cronos was recently granted a manufacturing license to produce cannabis-based products in Australia, and a new Polish distribution agreement will give the company a foothold in the European market.

CV Sciences, Inc. (OTC: CVSI) is firmly focused on the CBD sector. The company has two parts: a drug development division exploring novel CBD-based treatments and a consumer product division that manufactures, markets and sells the resulting products.

Some companies are focused on providing support and equipment for CBD cultivation. Terra Tech Corporation (OTC: TRTC) has created a hydroponic growing system that uses moving tables to increase yields by up to 30 percent while reducing costs by up to half. Its energy efficiency and recycling of waste water means that the company’s systems live up to the expectations of green-minded consumers.

Liberty Health Sciences (OTC: LHSIF) works in the medical cannabis market. As it acquires and operates U.S.-based cannabis companies, its aim is to produce safe, high-quality cannabis for patients. It has recently received Good Manufacturing Practice certification for its high standards of safety, consistency and quality.

Given the growing number of players in the cannabis market, a shift in the classification of CBD on a federal level could have a tremendous impact. For companies already focusing on CBD products, a huge opportunity for growth in the United States may be on the horizon.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Farm Bill Legislation May Springboard Federal Hemp Acceptance

CannabisNewsWire Editorial Coverage: The United States House passed the 2018 Farm Bill, which will redefine subsidies to farmers, nutritional welfare recipients, conservationists and others. Tucked into this bill of more than 1,000 pages is hemp legalization legislation supported by Senate Majority Leader Mitch McConnell. Demand – and thus farming revenue – for tobacco is waning, and McConnell says hemp farming could help bolster farming communities in his home state of Kentucky and across the country. Currently listed as a controlled substance under federal law, the new bill will declassify hemp as a schedule 1 drug and label it as a viable agricultural commodity. Through its hempSMART™ subsidiary, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is one example of a few companies currently providing consumers hemp plant-based products under the rubric of existing laws, and the company has undertaken broad-based legal hemp cultivation programs. Other companies that could feel the ripples of change in the space are Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV Sciences, Inc. (OTC: CVSI), Medical Marijuana, Inc. (OTC: MJNA), and Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) (LXRP Profile).

Hemp’s History

Archaeological evidence reveals that for over 10,000 years hemp has been used by humans for pottery, shoes, ropes, clothing, food, medicine, and a wide array of other applications. Since early populations ingested hemp seeds, it stands to reason they also discovered the medicinal properties found in the plant. Ancient Asia, Egypt, India, Greece and the Islamic world all have rich histories relating to medicinal cannabis. In the 19th century, cannabinoids gained popularity for therapeutic use in Western medicine, but regulatory efforts imposed strictures during the 20th Century, eventually leading to a ban on its use in the U.S. under federal drug controls because of hemp’s relation to its more drug-user-friendly cannabis counterpart, marijuana. But, in recent years, society has turned to modern science to substantiate anecdotal claims about the therapeutic efficacy of non-psychoactive cannabidiol (CBD) found in the hemp plant.

“I know there are farming communities all over the country who are interested in this,” McConnell told the Senate Agriculture Committee amid debate over his bill. “Mine are particularly interested in it, and the reason for that is — as all of you know — our No. 1 cash crop used to be something that’s really not good for you: tobacco. And that has declined significantly, as it should, given the public health concerns.”

The federal government has exhibited schizophrenic regulatory tendencies toward hemp since the passage of the Marijuana Tax Act of 1937 that quashed hemp production with exorbitant excise taxes.  Reversing course during WWII, the government urged farmers to grow hemp for fiber and also waived taxes, and over 400,000 acres of hemp were cultivated between 1942 and 1945. After the war, hemp again had persona non grata status. Congress then passed the Controlled Substances Act in 1970, prohibiting the use of all cannabis for any purpose whatsoever and effectively terminating all industrial hemp production. Hemp extracts, however, are considered legal because they contain less than 0.3 percent THC, but the cultivation of hemp remains federally verboten. Now, the advancement of the Farm Bill signals a revived federal interest in the industrial hemp industry.

Hemp Pioneers

Led by hemp industry pioneers, Marijuana Company of America, Inc. (OTC: MCOA) has spearheaded efforts and staked claims on multiple legal hemp cultivation projects. The company’s innovative strategy is to vertically integrate hemp production and sales – from seed to shelf. Cultivation of quality hemp will feed MCOA’s innovative CBD-based formulations, which use the highest-quality hemp to produce what could be the finest-quality botanical supplements on the market. The hempSMART™ product line contains tested levels of clinically researched ingredients to meet consumer needs that support the body’s natural endocannabinoid system.

From seed to shelf, MCOA has built its business model around industrial hemp-based CBD products. Hemp has a myriad of uses beyond CBD therapeutics – as a food, a natural fiber, and even as a commodity in the building materials sectors. No part of the plant goes unused, and MCOA’s overarching strategy is to capitalize at each profit point – from farm to finished products. MCOA appears to be establishing a commanding presence at multiple inflection points across the entire hemp value chain.

hempSMART™, Inc.

Expanding on ancestral wisdom, MCOA has combined the most effective ingredients in wellness technologies with pure plant-derived industrial hemp-based cannabinoids to create optimally formulated wellness products for health-conscious consumers.

hempSMART™ offers a number of different products within a wide range of delivery systems, such as its capsule-based formulations hempSMART™ Brain, a patent-pending nootropic product designed to support natural brain function; and hempSMART™ Pain, which is formulated with a blend of premium full-spectrum CBD and botanical supplements designed for pain associated with physical activity.

The company also offers sublingual CBD tinctures to customers including hempSMART™ Full-Spectrum Drops and their natural pet supplement hempSMART™ Pet Drops with advanced bioavailability.

hempSMART™ has also expanded upon its established line of products by offering topical products such as hempSMART™ Pain Cream, which is designed to provide temporary relief and soothe sore, aching muscles and joints. The company also launched a new cosmetic product, hempSMART™ Face, a CBD facial moisturizer that has been designed to refresh, replenish and restore skin cells on the face.

MCOA’s hempSMART™ CBD consumer products are sold at www.hempsmart.com.

Hemp Cultivation

In what appears to be a vertically integrated business strategy, MCOA entered into a joint venture with Global Hemp Group Inc. (OTC: GBHPF) to launch multiple industrial hemp cultivation projects in the legal marijuana states of the U.S. and in Canada. The first is a 125-acre industrial hemp cultivation project in northeast New Brunswick. The project is well under way with objectives of promoting hemp farming and attendant year-round jobs.

A certified professional agronomist, Joan Parker-Duivenvoorden, has been hired to manage the project. She has over 15 years of experience with the Nova Scotia Department of Agriculture and with the New Brunswick Soil and Crop Improvement Association, which will prove invaluable as the project expands to encompass and employ over 50 farmers.

Planting has been completed on the first 77 acres, and the remaining 48 acres will be seeded soon. Drying equipment is being evaluated to process the hemp after harvest, and management is already in discussions with several potential processing partners for extraction of cannabinoids. Once all the licenses have been acquired for importing and manufacturing finished CBD products, the New Brunswick site could easily serve as a distribution center for MCOA’s hempSMART™ subsidiary.

In another joint venture with Global Hemp Group, MCOA is also developing Covered Bridge Acres, a high-yielding CBD hemp cultivation project in Oregon. Operations at the farm are well under way. The project will utilize both traditional outdoor cultivation and what will be over 19,296 square feet of greenhouses.

“Our evolving project in Scio, Oregon, highlights the quality of the team in place as they continue to lean on their many years of experience cultivating hemp. Activities such as these will help to secure the raw oil that we will need for our hempSMART brand of CBD infused products,” stated Donald Steinberg, MCOA’s CEO.

The Takeaway

With rapidly expanding retail distribution and burgeoning, diversified hemp cultivation programs underway, MCOA is fast approaching the vertical integration that typically impacts bottom lines and drives shareholder value.

Other companies already operating in the CBD space include:

Isodiol International (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) grows and harvests hemp on an industrial scale and then processes it to extract cannabidiol (CBD) for worldwide distribution. The company pioneered the commercialization of 99 percent-plus pure, pharmaceutical-grade cannabinoids, micro-encapsulations and nanotechnology for consumable and topical skin care products.

CV Sciences (OTC: CVSI) operates in two business segments. The company’s drug development division develops and commercializes novel therapeutics utilizing synthetic CBD. Its consumer product division manufactures, markets and sells plant-based CBD products to a range of market sectors.

Medical Marijuana (OTC: MJNA) develops, distributes and sells hemp oil that contains naturally occurring cannabinoids, including CBD, and other products containing CBD oil. The company sells its hemp-derived CBD products through its distribution subsidiaries. The company was among the first to bring hemp-based CBD oil products to market in the United States.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) out-licenses its patented delivery technology, which lowers dosing of lipophilic active molecules and enhances their effectiveness. The company’s technology increases intestinal absorption rates, speeds delivery to the bloodstream, and masks tastes for orally administered bioactive molecules including cannabinoids, vitamins, NSAIDs, nicotine and other molecules.

Together, MCOA and these companies weave a tapestry of industry, innovation and intuitive concern for the communities they serve with nature-based hemp products that appear to be once again losing the stigma that has come from being marijuana’s staider sibling.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Dangers Lurking in Synthetic CBD Underscore Value of Quality Product

CannabisNewsWire Editorial Coverage: Dating back thousands of years, people have found ways to treat pain and other ailments with cannabidiol (CBD) oil which is harvested from the hemp plant. However, the natural healing properties of CBD are being jeopardized by the advent of man-made synthetic CBDs. These chemical analogs are dangerous imitations of plant-derived product, binding to human endocannabinoid receptors at astronomically larger quantities than natural cannabinoids. These designer drugs prompted the U.S. Centers for Disease Control and Prevention to issue a national health alert warning about synthetic cannabinoids. Shunning synthetics, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) provides consumers complete transparency and delivering only pure, plant-based 100% hemp-derived products through its hempSMART™ brand. While Medical Marijuana, Inc. (OTC: MJNA) and PotNetwork Holding, Inc. (OTC: POTN) market hemp-derived CBD products, some companies such as Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) and CV Sciences, Inc. (OTC: CVSI) utilize extraction techniques to produce isolated cannabinoid compounds for both commercial and/or research uses.

Surging Demand Creates Copy Cats

Hemp-derived CBD grew from a market category that didn’t exist five years ago to generating $190 million in sales in 2017. The U.S. industry is poised to reach $1 billion dollars in 2018, led by hemp-derived CBD, food, personal care and industrial products. Hemp Business Journal estimates the U.S. hemp industry will grow to a $2.6 billion market by 2022 with an estimated five-year CAGR of 25%.

In a recent article, “Fighting fakes: Hemp leaders on the dangers of synthetic CBD,” public health investigators issued warnings when 50 people were sickened after consuming synthetic CBD. What the epidemiologists found was that the products, while labeled CBD, did not contain CBD compounds. Instead, the products contained a synthetically produced cannabinoid.

CBD products are often mislabeled, both in how much CBD the products contain and where the CBD comes from. A study published in JAMA revealed that nearly 70% of online CBD marijuana extracts are mislabeled, some had extra CBD, some less, and some contained hidden CBDs. Blind testing found that only about 31% of the extracts tested contained the amount of CBD listed on the label.

Differentiated from Others

The company’s commitment to quality may differentiate Marijuana Company of America, Inc. (OTC:MCOA) from all others in the sector. MCOA uses the highest-quality sourced raw materials to produce the finest quality botanical supplements and topicals on the market. To ensure quality and transparency, the company’s hempSMART™ product line has been rigorously tested to validate its purity. Products developed by hempSMART are derived and formulated from industrial hemp containing naturally occurring CBD compounds that help support the body’s natural endocannabinoid system. All hempSMART™ products contain tested levels and clinically researched ingredients designed to meet and exceed consumers expectations.

The company is led by cannabis industry pioneer Donald Steinberg, MCOA’s CEO and an experienced veteran of the cannabis and industrial hemp industries. Steinberg founded the first marijuana company ever to trade on a U.S. stock market, and his extensive background and knowledge of the industry may give the company unparalleled insights into the global industrial hemp and cannabis markets.

Celebrated Family of Products

Derived from industrial hemp containing CBD compounds, MCOA’s hempSMART™ product line is among the finest quality of botanical supplements on the market. Scientifically driven, each of MCOA’s hempSMART™ products are created to ensure only the highest quality products reach discerning consumers. MCOA’s hempSMART™ CBD consumer products are researched, developed and sold at www.hempsmart.com.

The company recently re-launched its patent-pending wellness nootropic product hempSMART™ Brain, a “first of its kind” researched formulation for optimal brain function support, with 300mg of full spectrum CBD per bottle. HempSMART products also include full spectrum bioavailable CBD drops in form of a tincture containing a high concentration and potency of CBD, hempSMART ™ Pain capsules with a blend of premium CBD and botanical supplements, and hempSMART ™ Pain Cream with a synergistic combination of natural botanicals and full spectrum hemp extract to treat aching muscles and joints. In addition, the company now provides hempSMART™ Full Spectrum Pet Drops, exclusively designed for fur-bearing family members.

To virally expand sales, MCOA created its own unique hempSMART affiliate network marketing program. The affiliate marketing program provides a generous compensation plan to promote and sell hempSMART’s CBD consumer products in the United States. Advocates of hempSMART’s CBD products make the best ambassadors and the sales model lends itself to rapid global expansion.

Diversified Opportunity

In addition to the research and development of hemp-based consumer products, MCOA is strategically expanding its footprint across multiple facets of the hemp industry, building a portfolio of diversified investments and joint ventures to grow the company and potentially drive shareholder value.

The company recently provided updates on its 125-acre industrial hemp cultivation project in northeast New Brunswick with joint-venture partner Global Hemp Group Inc. (OTC: GBHPF). Planting on the first 77 acres is complete and the remaining 48 acres will be seeded soon. Drying equipment is being evaluated to process the biomass after harvest and management is in discussions with several potential processing partners for the material.

To target impulse buys in high traffic convenience stores, MCOA secured a 25% equity stake in Convenient Hemp Mart, LLC’s BeniHemp branded products. BeniHemp products will include topicals, tinctures, and edibles packaged in one-day, two-day, and 30-day supplies distributed to convenience stores, smoke shops, gas stations and similar small retail businesses.

Each owning 42.5%, MCOA and Global Hemp Group formed a joint venture, Covered Bridge Acres LTD., to develop a high yielding CBD hemp cultivation project in Oregon and committed to jointly invest a total of US$1.2 million into the project. A cornerstone of the project is the acquisition of a 109-acre agricultural property in Scio, Oregon. The property, located 70 miles south of Portland, is situated in the fertile Willamette Valley and has a history of hemp cultivation over the past two years. The farm is ideal for cultivating hemp as it contains a high level of organic matter in the soil and has an established irrigation infrastructure with sufficient water rights.

MCOA successfully raised $1 million in funding for Bougainville Ventures to construct and manage a turnkey state of the art cannabis cultivation and processing facility. The joint venture has completed the setup of 10,000 sq. ft. of greenhouse space and waiting for completion of inspection, the final step before commencing cultivation.

Active Companies Vying for Market Position

CV Sciences (OTCQB: CVSI) operates two business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing naturally occurring CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The company recently announced the June 7, 2018, publication of the toxicology and safety results of an extract from the base raw materials used in its PlusCBD Oil™ consumer products. The study, designed to investigate the safety of oral consumption of the company’s hemp CBD oil and to support a Generally Recognized as Safe (GRAS) Independent Conclusion, concluded that the test article was non-mutagenic, non-clastogenic and non-genotoxic.

Isodiol International (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is focused on pharmaceutical grade phytochemical compounds and is among industry leaders in the manufacture and development of consumer products. The company pioneered the commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for consumable and topical skin care products. Isodiol earlier this month entered into a binding agreement to acquire 51% of Round Mountain Technologies, LLC (“RMT”), a cultivator of organic hemp with operations in Nevada.

Medical Marijuana (OTC: MJNA), the first publicly traded cannabis company in the United States (founded by current CEO of Marijuana Company of America Don Steinberg), develops, distribute and sells hemp oil that contains naturally occurring cannabinoids, including CBD and other products containing CBD oil. In recent news, MJNA announced its favor on the Drug Enforcement Administration’s (DEA) recent statement on the legality of CBD — which further clarifies that some CBD products, such as hemp-derived CBD products, are legal to distribute throughout the United States and do not fall under the regulations of the Controlled Substances Act (CSA). Additionally, the company’s HempMeds® subsidiary reported the historic authorization of its Real Scientific Hemp Oil-X™ (RSHO-X™) CBD hemp oil product for import into Argentina.

PotNetwork Holding (OTC: POTN) is a holding company for its subsidiaries, First Capital Venture Co. that owns Diamond CBD, Inc., the maker of Diamond CBD oils. Diamond CBD researches, develops and markets hemp extracts that contain a broad range of cannabinoids and hemp derivatives. The company recently announced that Diamond CBD’s online sales increased 639% higher than the year prior. PotNetwork is in currently preparing to file with the SEC to become a fully reporting company.

With an estimated 25% compound annual growth rate, there’s little doubt the about the trajectory of the CBD market. As the market continues its rapid expansion and more people become aware of the dangers lurking in synthetic CBD, it seems reasonable that evermore consumers will gravitate toward high-quality natural CBD product. Companies like MCOA aim to answer that call.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

CBD Market Set for Huge Growth

CannabisNewsWire Editorial Coverage: In a fragile economic world, industries with significant growth forecast are certain to catch the eye of savvy investors looking for just the right place to be. Recent reports indicate that the cannabidiol (CBD) market is estimated to grow by 700 percent by 2020, and a report by market intelligence firm Hemp Business Journal projects that the CBD market will grow to $2.1 billion by 2020 (http://cnw.fm/7iczS), an astronomical jump in value compared to last year’s CBD market of $202 million. This news bodes well for hemp-focused companies such as Marijuana Company of America (OTC: MCOA) (MCOA Profile), whose hempSMART™ brand will be among the first CBD products to be marketed on a mass national TV commercial. Growth in hemp-based products is only a piece of the cannabis industry puzzle. The entire legal cannabis industry is expected to hit $57 billion by 2027, with recreational marijuana use making up 67 percent of that and medical marijuana use taking up the remaining 33 percent. Other companies positioning themselves to take advantage of this incredible growth include AbbVie, Inc. (NYSE: ABBV), CV Sciences, Inc. (OTCQB: CVSI), KushCo Holdings, Inc. (OTCQB: KSHB), and Aurora Cannabis, Inc (OTCQX: ACBFF).

Capitalizing on the Power of CBD

Studies show that cannabidiol (CBD) possesses an array of therapeutic benefits, including antioxidant and neuroprotective properties. One of more than 85 cannabinoids identified in marijuana and hemp, CBD is typically used for health reasons and, unlike the more widely recognized compound tetrahydrocannabinol (THC), is not psychoactive, meaning it doesn’t cause a high. CBD products can be derived from industrial hemp plants or marijuana plants.

Marijuana Company of America (MCOA Profile), an industrial hemp company, has capitalized on the power of CBD through its product research and development of legal hemp-based consumer products under the hempSMART brand, which targets general health and well-being. The products, which include drops and creams, are formulated to produce the finest botanical supplements on the market, derived from industrial hemp containing CBD compounds that help support the bodies endocannabinoid system.

A National Market Strategy and TV Commercial

 Earlier this month, MCOA announced (http://cnw.fm/WxIg1) that it had engaged Kim Castle of Verve Integrative to create a market strategy and manage a direct response television ad campaign to promote its hempSMART product line. Initially, hempSMART will be working with Verve Integrative to develop a market strategy and television commercial for its hempSMART Full Spectrum Pet Drops, which will air on cable networks this summer. The commercial spot will have featured placement on the official ecommerce site of a popular direct-response TV company and will be broadly promoted on integrated social media outlets.

“We are very pleased to partner with hempSMART on their journey to bring such thoughtful and well-developed products to the people who need natural relief and enhanced health solutions. I wish hempSMART™ Pet Drops were available to support my cherished dog when we were going through a health challenge together,” said Castle, who, along with her team, bring more than 25 years of experience in many variations of media strategy, development and production. Their clients include Disney, GM, ABC, Paramount, and Grey Group.

The team specializes in multipoint story experiences designed to educate, entertain and endorse while mirroring the human mind’s process of solving a problem, thereby supporting consumers in making emotional and logical product conclusions. Castle’s experience provides an invaluable edge to the hempSMART marketing campaign. Castle has also been an outspoken advocate of CBD as an alternative to traditional products currently on the market.

MCOA CEO Donald Steinberg noted that “Kim’s experience gives us an excellent opportunity to greatly expand the marketing strategy for the hempSMART brand and product line. We are honored that the hempSMART product line will be managed by her and the Verve Integrative team. We look forward to the new television commercial airing this summer.”

Pet Supplement Market Expanding

MCOA just launched its hempSMART Full Spectrum Pet Drops in February. The new specially formulated product contains naturally occurring CBD derived from hemp seed oil, full spectrum hemp extract, and fractionated coconut oil, along with a rich bacon flavor.

Sales of natural pet supplement sales nearly doubled between 2008 and 2011, and with an increasing focus on pet health, the market for pet supplements is projected to show significant and continuing expansion (http://cnw.fm/66NhV). Estimates show that U.S. retail sales of pet supplements and nutraceutical treats will grow 3 to 5 percent annually, bringing the market to almost $1.6 billion. Globally, the pet supplement market is also expected to experience tremendous growth.

Steinberg said, “Our new hempSMART product is a natural option for pet owners who care about supporting their animals’ healthy energy levels as well as optimizing their health. Our hempSMART product line will continue to expand to other popular areas of consumer interest to give our affiliates what they need to succeed.”

Wellness Environment Shifting toward CBD

The wellness industry is growing rapidly, generating an estimated $3.72 trillion annually (http://cnw.fm/d3Zs5). In addition, the attitude in the wellness environment is shifting regarding premium quality cannabinoid products. MCOA is one of the prominent companies working to give consumers access to technological innovations and the highest quality hemp-derived products.

Specifically designed to support normal bodily functions such as energy, flexibility, and overall wellness, hempSMART products are only the beginning for MCOA and its hempSMART division. MCOA is committed to find, test, and deliver the finest natural ingredients focused on wellness and personal care combined with the added benefits of hemp-based cannabinoids.

In addition to dedicating itself to the development of CBD-based nutritional products, MCOA is focused on educating and empowering consumers to learn about and become part of the hemp movement, thus allowing its customers to benefit from some of the world’s most innovative hemp products. The company is also dedicated to supporting the resurgence of green sustainable hemp-based products and technologies that have a positive effect on the environment.

Others Positioning in the Market

MCOA isn’t the only company deeply committed to making its presence felt in the burgeoning hemp and cannabis industries.

AbbVie (NASDAQ: ABBV) is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. With a cannabis-based drug already available on the market, pharmaceutical company AbbVie, is ahead of the pack in this industry. Its FDA-approved Marinol is approved for chemotherapy-induced nausea and vomiting and anorexia, and the drug may also help AIDS patients who have lost their desire to eat.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The company’s PlusCBD Oil™ has achieved immense success since the launch of its brand of dietary supplements. The brand is currently being sold in approximately 1,300 health food stores and continues to grow its shelf presence in various retail outlets across the country. “It’s evident that hemp-derived CBD products are doing better and growing faster than almost every other category in the supplement industry, and it’s been a long time since we’ve seen a supplement trend truly demonstrate demand in such an immense fashion,” said Stuart Tomc, vice president of human nutrition and spokesperson for CV Sciences. “There are no barriers to acceptance as the idea of hemp-derived CBD is finally ripe. Consumers are embracing hemp-derived CBD.”

The premier packaging company in the rapidly growing legal, regulated marijuana industry, KushCo Holdings, Inc. (OTCQB: KSHB) is a dynamic sales and distribution platform that provides packaging, supplies, vaporizer products, hydrocarbons, accessories, and branding services to cannabis manufacturers, processors and retailers. Founded in 2010, Kush Bottles now has 12 facilities throughout the United States, a sales presence in every major cannabis market, and strives to be the go-to supplier and thought leader for businesses in the cannabis industry. KushCo recently announced that it had partnered with MainStem, a technology-based ancillary product distribution company for the regulated cannabis industry, to be the inaugural partner for MainStem’s Vendor Program (MVP).

An industry leading producer of medical cannabis, Aurora Cannabis, Inc (OTCQX: ACBFF) operates a 55,200-square-foot, state-of-the-art production facility in Mountain View County, Alberta, and a second 40,000-square-foot, high-technology production facility in Pointe-Claire, Quebec. In January 2018, Aurora’s 800,000 square-foot-flagship cultivation facility located at the Edmonton International Airport was licensed. When at full capacity, this facility is expected to produce over 100,000 kg per annum of cannabis. Aurora is also completing a facility in Lachute. In addition, the company just announced its intention to acquire MedReleaf Corp. (TSX: LEAF). This proposed transaction will bring together two of Canada’s premier cannabis companies with fully aligned strategic visions and production philosophies, as well as complementary assets, distribution networks, products, and capabilities. The combined company will meet what Aurora and MedReleaf management teams consider to be the critical success factors in the industry, creating a powerful platform for accelerated growth on a global scale.

For more information about Marijuana Company of America, please visit Marijuana Company of America (MCOA).

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.